Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model

DNA and Cell Biology

Volumn 24, Issue 7, 2005, Pages 470-475

  Xu, Qing ^a,c   Brabham, Jeffrey G ^a,d   Zhang, Shumin ^a   Munster, Pamela ^a   Fields, Karen ^a   Zhao, Ruan Jin ^b   Yu, Hua ^a,e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Center for Traditional Chinese Medicine   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BING DE LING; CHINESE DRUG; FLUOROURACIL; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CACHEXIA; CANCER GRAFT; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HERBAL MEDICINE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; COLONIC NEOPLASMS; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; SURVIVAL RATE; TIME FACTORS; UP-REGULATION;

EID: 22244435245     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2005.24.470     Document Type: Article

References (18)

1. ANDREYEV, H.J., NORMAN, A.R., OATES, J., and CUNNINGHAM, D. (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies. Eur J. Cancer 34, 503-509.
2. BERNSTEIN, B.J., and GRASSO, T. (2001). Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt). 15, 1267-1272.
3. BOON, H., STEWART, M., KENNARD, M.A., GRAY, R., SAWKA, C., BROWN, J.B., MCWILLIAM, C., GAVIN, A., BARON, R.A., AARON, D., et al. (2000). Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J Clin Oncol. 18, 2615-2521.
4. BRAUN, A.H., ACHTERRATH, W., WILKE, H., VANHOEFER, U., HARSTRICK, A., and PREUSSER, P. (2004). New systemic front-line treatment for metastatic colorectal carcinoma. Cancer 100, 1558-1577.
5. CHATTERJEE, M., OSBORNE, J., BESTETTI, G., CHANG, Y., and MOORE, P.S. (2002). Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 298, 1432-1435.
6. CORBIN WINSLOW, L., and SHAPIRO, H. (2002). Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch. Intern. Med. 162, 1176-1181.
7. IIZUKA, N., HAZAMA, S., YOSHIMURA, K., YOSHINO, S., TANGOKU, A., MIYAMOTO, K., OKITA, K., and OKA, M. (2002). Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int. J. Cancer 99, 286-291.
8. INADERA, H., NAGAI, S., DONG, H.Y., and MATSUSHIMA, K. (2002). Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. Int. J. Cancer. 101, 37-45.
9. KURZROCK, R. (2001). The role of cytokines in cancer-related fatigue. Cancer 92, 1684-1688.
10. NIU, G., TAN, J., TURNER, J.G., BRABHAM, J.G., BURDELYA, L.G., CRUCIAN, B.E., WALL-APELT, H., ZHAO, R.J., and YU, H. (2000). Bing de ling, a Chinese herbal formula, stimulates multifaceted immunologic responses in mice. DNA Cell Biol. 19, 515-520.
11. NUKATSUKA, M., FUJIOKA, A., SAITO, H., NAKANO, K., UCHIDA, J., OH-IE, S., NOMURA, N., TAKEDA, S., UNEMI, N., ISHITANI, K., et al. (1994). Antitumor and anticachectic activity of UFT in BALB/c mice bearing colon 26 adenocarcinoma. Gan To Kagaku Ryoho 21, 2013-2020.
12. PFITZENMAIER, J., VESSELLA, R., HIGANO, C.S., NOTEBOOM, J.L., WALLACE, D., Jr., and COREY, E. (2003). Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97, 1211-1216.
13. RICHARDSON, M.A., SANDERS, T., PALMER, J.L., GREISINGER, A., and SINGLETARY, S.E. (2000). Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 18, 2504-2514.
14. SHEN, J., ANDERSEN, R., ALBERT, P.S., WENGER, N., GLASPY, J., COLE, M., and SHEKELLE, P. (2002). Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med. 2, 8.
15. TAMATANI, T., AZUMA, M., ASHIDA, Y., MOTEGI, K., TAKASHIMA, R., HARADA, K., KAWAGUCHI, S., and SATO, M. (2004). Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int. J. Cancer 108, 912-921.
16. TRIKHA, M., CORRINGHAM, R., KLEIN, B., and ROSSI, J.F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin. Cancer Res. 9, 4653-4665.
17. WILKE, H.J., and VAN CUTSEM, E. (2003). Current treatments and future perspectives in colorectal and gastric cancer. Ann. Oncol. 14(Suppl 2):ii49-55.
18. YAMAMOTO, S., KUREBAYASHI, J., KUROSUMI, M., KUNISUE, H., OTSUKI, T., TANAKA, K., and SONOO, H. (2001). Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. Cancer Chemother. Pharmacol. 48, 283-288.